Entopsis has licensed cutting-edge research tools from its new PCRopsis™ product line for the Chinese market to Beijing Wan Bridge Intelligent Technology. Backed by patent pending technologies, PCRopsis™’s three cost- and time-saving solutions for sample processing are expected to usher in a new direction for laboratory R&D.
Miami, Florida, July 9, 2018: Leading biotech R&D company Entopsis has recently licensed three state-of-the-art PCRopsis™ technologies aimed at the lucrative Chinese life sciences market. Launched a few months ago in the United States, PCRopsis™ is Entopsis’ new product line focused on providing cost- and time-saving solutions for clinical and research labs. PCRopsis™ was created to greatly simplify sample processing steps, reduce cost and address bottlenecks in lab automation processes, while delivering test-ready samples of high quality.
“We are excited to exclusively license our latest PCRopsis™ technologies. This deal validates our team’s commitment to providing efficient and effective biotech solutions on a global scale,” stated Dr. Obdulio Piloto, Entopsis CEO and co-founder. Entopsis’ CFO Dr. George Huang elaborated that “Entopsis will be receiving a minimum of $2.8M in revenue over three years with expected revenue projections of more than $6.25M in this period.”
All PCRopsis™ products are meant to address key problems and improve efficiency in laboratory research & development with their unique capabilities. Each of them is USA manufactured in a certified ISO13485/ISO9001 facility to ensure compliance with the highest quality standards. The following three PCRopsis™ products are licensed exclusively for the Chinese market.
PCRopsis™ Cell is a revolutionary tool which allows for direct PCR from cellular samples without DNA isolation or centrifugation, in under 20 minutes, making it fast and easily automatable. Further, the PCRopsis™ Cell kit can process diverse and mixed cellular samples containing bacteria, mammalian cells and fungi, offering breadth and scope unmatched by competitors.
PCRopsis™ Blood Cell Separator is engineered to separate white blood cells, or specific cell types, from red blood cells starting with whole blood. This unique cell separation approach does not require density media, magnets, centrifugation or specialized equipment. PCRopsis™ Blood Cell Separator is expected to disrupt lab automation by providing a one-step automation-friendly alternative to the currently labor-intensive Ficoll®-Paque protocol.
PCRopsis™ Concentrator offers a simple, quick and hands-free means of concentrating samples. The first of its kind, the tool concentrates DNA, proteins and cells within five minutes without the need for any equipment. PCRopsis™ Concentrator impacts numerous areas of research where concentration of analytes is critical to assay sensitivity. Such areas include clinical diagnostics, proteomics, metabolomics, and microbiomics.
Entopsis is the only Florida-based start-up supported by the Thiel Foundation’s Breakout Labs, which backs ground-breaking companies developing deep science technologies. Entopsis is best known for OpsisDx®, its diagnostic platform which distinguishes multiple medical conditions from a single urine sample without the need for analyzing DNA, RNA or circulating tumor cells. The OpsisDx® platform is currently being tested in clinical studies.
Incomplete access to DNA from lysed cells is a common problem in PCR studies. This issue is often caused by inadequate cell lysis and low concentrations of DNA in the sample. Traditionally, cells are lysed with detergents and enzymes (i.e., Proteinase K) followed by a DNA isolation step (e.g., Qiagen's QIAamp DNA Kit). This approach works well for many cell types, although it fails with some cell types, is time consuming, involves many steps and DNA is often lost during the DNA isolation step.
An alternative approach, that gets around these deficiencies, does not use enzymes to lyse cells or involve DNA isolation. Instead it relies on a mild detergent to weaken cell membranes / walls followed by a heating step to lyse cells (e.g., 5x Cell Lysis Buffer by PCRopsis). This lysate is then incubated with PCRopsis Cell tubes to remove PCR inhibitors that interfere with PCR. This approach allows one to thoroughly lyse numerous cell types (i.e., mammalian, bacterial, fungal, etc.) with a common approach in just a few steps, without lost of DNA or use of expensive, specialized consumables (e.g., columns, magnetic beads, etc.). The PCRopsis alternative approach is ideal for samples containing more than one microorganism, where you need to ensure you detect each microorganism.
Below are a few studies using the PCRopsis approach:
Study #1: Detecting bacterial, yeast and human DNA
Study #2: Detecting bacteria from urine patient samples
Study #3: Detecting toe nail fungi
See all studies at: www.pcropsis.com/studies.html
Short answer... yes, for E. coli and S. aureus. Other bacteria are being tested.
There is great value in detecting microorganisms and tumor cells in urine and blood samples. To date, DNA from cells in samples has been isolated and then used in PCR for detection of relevant DNA fragments. However, the process of isolating DNA results in the lost of some DNA and involves a number of steps, opening the possibility for error and contamination. Alternatively, cells within samples can be lysed at 95°C ~ 100°C and the released DNA directly used for PCR, without any lost of DNA in a simple, mostly error-free fashion. However, lysed cells release molecules that interfere with PCR and potentially leading to a lack of DNA amplification.
To answer the question posed in the title, our team compared DNA recovered from thermally lysed cells in urine or plasma and processed using PCRopsis tubes to DNA recovered from the same samples using Qiagen's QIAamp® DNA Kit. We used PCRopsis 5x PCR Master Mix to ensure we obtain optimal PCR amplification. The relevant results and statistical analysis are in the link below. In summary, one can detect DNA fragments from thermally lysed cells within urine or plasma that were processed with PCRopsis tubes to a level that's statistically comparable to Qiagen's QIAamp® DNA Kit.
The PCRopsis tubes offer the following advantages over QIAamp® DNA Kit:
Other Related Studies:
Sepsis is a systemic inflammatory state due to an infection, and is associated with very high mortality and morbidity. Early diagnosis and prompt antibiotic and supportive therapy is associated with improved outcomes. Bacteremia (presence of bacteria in blood) along with a systemic inflammatory response denotes sepsis. Sepsis is responsible for nearly 10% of the ICU admissions in the United States, totaling about 1 million cases nationwide every year (1). The incidence rate of severe sepsis in the United States is about 300 per 100,000 persons per year, with a total of 750,000 cases nationwide per year. Direct costs per sepsis patient for ICU treatment in the United States have been estimated at more than $40,000. The risk of mortality increases by 7.6% with every 1 hour delay in administering antibiotic therapy in septic shock patients with hypotension (2-3).
PCR-based tests for the early diagnosis of sepsis. Where do we stand?(4) Rapid and accurate identification of the cause of sepsis is essential in improving patient outcomes. Early identification of these pathogens by nucleic acid detection assays directly from blood samples remains key to achieving this, particularly if taken at the time of presentation. Selection of the most suitable PCR system is typically influenced by local epidemiology and by the resources of the testing laboratory.
PCRopsis Blood can speed-up the detection of bacteria in blood samples by enabling testing laboratories to perform direct PCR from clinical samples without having to isolate DNA.
Read more at: www.pcropsis.com/pcropsis--sepsis.html